Qual é o preço para EFFECTOR Therapeutics, Inc. (EFTRW)

O preço para EFFECTOR Therapeutics, Inc. (EFTRW) é $0.0006

Qual é a capitalização de mercado para EFFECTOR Therapeutics, Inc. (EFTRW)

A capitalização de mercado para EFFECTOR Therapeutics, Inc. (EFTRW) é $2.82K

EFFECTOR Therapeutics, Inc. (EFTRW) LPA

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

Ano	EPS	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

EPS

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	EPS	Diferença de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$13.70	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Empresa

EPS

Diferença de EPS

País